Congestive heart failure disease management program: 1-Year population experience from a tertiary center heart failure registry in Saudi Arabia

• Main Authors: Khal Salem, Dania Fallata, Maha ElSebaie, Ahmad Montasser, Khaled ElGedamy, Osama ElKhateeb
• Format: Article
• Language: English
• Published: Saudi Heart Association 2017-04-01
• Series: Journal of the Saudi Heart Association
• Subjects: Heart failure; Disease management program; Middle East; Saudi Arabia
• Online Access: http://www.sciencedirect.com/science/article/pii/S1016731516301270

Aims: We aimed to evaluate congestive heart failure (CHF) multidisciplinary disease management program (DMProg) impact on mortality, readmission rates, length of stay (LOS), and gender health characteristics. Methods and results: This was a quasi-observational, pre- and post-trial with a parallel nonequivalent group. We enrolled 174 inpatients having CHF with reduced ejection fraction and New York Heart Association (NYHA) Class II–IV, and a total of 197 hospital admissions. A comparative follow-up was performed from 15 December 2014 to 15 December 2015. Among 197 consecutive hospital admissions, 76 (39%) were included in the preintervention or usual care group and 121 (61%) were assigned to the postintervention group. After 1 year, in comparison with the preintervention group, the postintervention group had shorter average LOS in days (7.6 days vs. 11.1 days, p < 0.002), lower 1-year readmission rate (36% vs. 57%, p < 0.003), and lower in-house mortality (1.6% vs. 7.8%, p = 0.03), but similar baseline mortality scores (38.2 vs. 38.6, p = 0.7), 30-day and 90-day readmission rates (15% vs. 18.3%, p = 0.62 and 27.6% vs. 30%, p = 0.65), and 30-day readmission risk score (24.9% vs. 26.2%, p = 0.09). By regression analysis, the DMProg intervention was an independent factor for 1-year readmission reduction (p = 0.001). Kaplan–Meier survival analysis favored the postintervention group (log-rank, p < 0.001). Conclusion: DMProg significantly decreased 1-year readmission rates, LOS, and in-house mortality.